Hims & Hers Health (NYSE:HIMS) Posts Earnings Results, Beats Expectations By $0.26 EPS

Hims & Hers Health (NYSE:HIMS) released its quarterly earnings data on Monday. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26, Briefing.com reports. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the previous year, the company earned ($0.04) earnings per share. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. Hims & Hers Health updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Hims & Hers Health Trading Down 0.6 %

NYSE:HIMS opened at $20.64 on Wednesday. The stock has a 50-day moving average price of $18.10 and a 200 day moving average price of $18.19. The stock has a market capitalization of $4.43 billion, a P/E ratio of 258.03 and a beta of 1.06. Hims & Hers Health has a 12-month low of $6.23 and a 12-month high of $25.74.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the sale, the insider now directly owns 169,935 shares of the company’s stock, valued at $3,935,694.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Michael Chi sold 7,500 shares of the firm’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00. Following the completion of the transaction, the insider now owns 193,980 shares in the company, valued at $4,306,356. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Soleil Boughton sold 2,339 shares of the stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total value of $54,171.24. Following the transaction, the insider now directly owns 169,935 shares of the company’s stock, valued at approximately $3,935,694.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 650,659 shares of company stock valued at $11,712,198. Corporate insiders own 17.71% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of research reports. Bank of America raised their price target on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Piper Sandler restated a “neutral” rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday. TD Cowen increased their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Finally, Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.